Evidence map›Paper›PMID 34864962›Full record

Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study.

Matthew A Spinelli, Michael J Peluso, Kara L Lynch, Cassandra Yun, David V Glidden, Timothy J Henrich, Steven G Deeks, Monica Gandhi

Abstract readObservational Study
In one paragraph

Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. The immune response to SARS-CoV-2 in people with HIV.Cellular & molecular immunology · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew A SpinelliDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-6368-8664
Michael J PelusoDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Kara L LynchDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
Cassandra YunDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Timothy J HenrichDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Steven G DeeksDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Monica GandhiDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)K23MH122286 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPINELLI, MATTHEW A. · 2020 to 2024
$1.0M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 VaccinesR21AI167648 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2022 to 2023
$444k
Developing a Mentoring Network of Diverse Mental Health ProfessionalsR24MH094274 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2011 to 2012
$371k
NIAID NIH HHS K23 AI157875NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI158013NIAID NIH HHS R21 AI167648NIMH NIH HHS K23 MH122286
6 · The paper itself

Abstract

Following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination, people living with human immunodeficiency virus (HIV, PLWH) had lower surrogate virus neutralization test response (P = .03) and a trend toward lower immunoglobulin G (IgG) response (P = .08), particularly among those with lower CD4+ T-cell counts and who received the BNT162b2 vaccine. Study of the impact of supplemental vaccine doses among PLWH is needed.

Indexed as

COVID-19Viral VaccinesAntibodies, ViralBNT162 VaccineCase-Control StudiesHIVHumansImmunoglobulin GNeutralization TestsRNA, MessengerSARS-CoV-2VaccinationAntibodies, ViralBNT162 VaccineImmunoglobulin GRNA, MessengerViral VaccinesCOVID-19HIVimmune responseSARS-CoV-2vaccination

Identifiers

PMID34864962
PMCPMC8689738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.